RMTI | Rockwell Medical, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.78 - 4.03
52 Week Range	1.1600 - 4.57
Beta	2.29
Implied Volatility	178.21%
IV Rank	19.52%
Day's Volume	438,079
Average Volume	550,896
Shares Outstanding	31,030,200
Market Cap	120,707,478
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1998-01-27

Valuation
Profitability
Growth
Health
P/E Ratio	-25.93
Forward P/E Ratio	-0.51
EPS	-0.15
1YR Price Target	18.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	237
Country	USA
Website	RMTI

Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company's drug products are Triferic. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The company operates in one segment of the hemodialysis market which involves the exports, manufacture, sale, and distribution of hemodialysis products. Key revenue is generated from the United States.

RMTI's peers: ESPR, LFCR, KMDA, ITCI, AGRX, EGRX, RGC, PROC, CPIX, IXHL, AQST, EVOK, ADMP, GHSI, ACRX, SXTC, BFRI, HUGE, ACOR, LSDI, COLL, PAHC, ANIP, SSIC

*Chart delayed

Analyzing fundamentals for RMTI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is very weak. For more detailed analysis please see RMTI Fundamentals page.

Watching at RMTI technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RMTI Technicals page.